Growth in this market is attributed to the growing
drug & alcohol consumption and the enforcement of stringent laws mandating
drug & alcohol testing, rising regulatory approvals for drug screening products
& services
Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=162987773
Drug screening tests help analyze and diagnose
biological samples such as blood, hair, and urine, and help detect the presence
of drugs of abuse or its metabolites in a person's body.
Market Segmentation
Based on the product, the drug screening market is segmented into
analytical instruments, rapid testing devices, and consumables. the analytical
segment is expected to dominate the market with a share of 53.0%.
By sample type, drug
screening market is segmented into urine, breath, oral fluid, hair, and other
samples. Among these, the urine sample segment is expected to account for the
largest share of 61.5%
Based on service and product, the drug screening market is segmented into
services and products. The services segment accounted for the largest share of
57.4% of the drug screening market.
Regional Analysis
North America is expected to dominate the market
with a share of 48.2%, followed by Europe. The large share of this geographical
segment is attributed to factors such as growing consumption of illicit drugs,
the availability of government funding to curb drug abuse, laws supporting drug
screening, the growing burden of accidents due to alcohol impairment, and the
presence of key players in the region are driving the growth of the drug
screening market in this region.
Key Market Players
The drug screening market is highly competitive
with the presence of several small and big players. Some of the players
offering products for drug screening market include Abbott Laboratories (US),
Thermo Fisher Scientific (US), Quest Diagnostics (US), Alfa Scientific Designs
(US), Roche (Switzerland), OraSure Technologies (US), MPD Inc. (US), and
Shimadzu (Japan).
Expected Revenue Growth:
The global drug screening market is
projected to reach USD 11.6 billion by 2026, from USD 5.3 billion in 2021, at a
CAGR of 16.8% during the forecast period.
LabCorp (US): LabCorp is a leading player in the US
drug screening services market. The company’s leading position is attributed to
its wide drug testing portfolio, including over 4,800 tests.